MedTrace Logo

Presepsin (sCD14-ST) for Prediction of Perioperative Risk - MET-REPAIR Nested Cohort Study

NCT03489486 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1695

Last updated 2018-09-25

No results posted yet for this study

Summary

Multicentre international prospective cohort study designed to evaluate whether preoperative presepsin (sCD14-ST) is associated with the composite endpoint: all-cause mortality and major adverse cardiovascular or cerebrovascular events (MACCE) after elevated risk non-cardiac surgery. If so:

1. What is the optimal cut-off for presepsin to predict the composite endpoint all-cause mortality and MACCE?
2. Does the calculated optimal cut-off improve prediction of the composite endpoint all-cause mortality and MACCE when added to clinical data and established biomarkers?

Conditions

  • Non Cardiac Surgery

Sponsors & Collaborators

  • European Society of Anaesthesiology

    collaborator OTHER

  • University Hospital Heidelberg

    lead OTHER

Principal Investigators

  • Jan Larmann, MD/PhD · Department of Anesthesiology, Univeristy Hospital Heidelberg

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-15
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03489486 on ClinicalTrials.gov